SEC Filings TLDR

On August 1, 2025, Randel Richner, a director of Lifeward Ltd., acquired 35,920 ordinary shares through restricted stock units (RSUs) granted under the Lifeward Ltd. 2025 Incentive Compensation Plan. The RSUs vest ratably in four equal quarterly installments starting three months after the grant date. Following this tr...

On August 1, 2025, Lifeward Ltd. (ticker: LFWD) reported a transaction involving Hadar Levy, a director of the company. Levy acquired 35,920 ordinary shares through the vesting of restricted stock units (RSUs) granted under the Lifeward Ltd. 2025 Incentive Compensation Plan. The RSUs vest ratably in four equal quarterl...

Joseph E. Turk Jr., a director of Lifeward Ltd., reported ownership of 86,457 ordinary shares as of August 1, 2025. This includes 71,839 shares issuable upon the vesting of restricted stock units (RSUs) granted on the same date under the Lifeward Ltd. 2025 Incentive Compensation Plan. The RSUs vest ratably in four equa...

On August 1, 2025, John William Poduska Sr., a director of Lifeward Ltd., acquired 35,920 ordinary shares through the vesting of restricted stock units (RSUs) granted under the Lifeward Ltd. 2025 Incentive Compensation Plan. The RSUs vest ratably in four equal quarterly installments starting three months after the gran...

On August 1, 2025, Lifeward Ltd. granted 35,920 ordinary shares to Robert J. Marshall Jr., a director of the company, in the form of restricted stock units (RSUs) under the Lifeward Ltd. 2025 Incentive Compensation Plan. The RSUs will vest ratably in four equal quarterly installments starting three months after the gra...

On August 1, 2025, Michael Swinford, a director of Lifeward Ltd., reported changes in his ownership of the company's ordinary shares. Swinford acquired 35,920 ordinary shares through the vesting of restricted stock units (RSUs) granted under the Lifeward Ltd. 2025 Incentive Compensation Plan. These RSUs vest ratably in...

On December 12, 2024, Michael A. Beindorff, a director of Lifevantage Corp (LFVN), reported changes in his ownership of the company's common stock. Beindorff disposed of 17,185 shares directly, reducing his direct holdings to 26,983 shares. Concurrently, he acquired 17,185 shares indirectly through the Michael A. Beind...

On August 5, 2025, NLIGHT, INC. (ticker: LASR) reported a transaction involving its Chief Accounting Officer, Nias James. The filing indicates that James acquired 8,000 restricted stock units (RSUs) representing the right to receive shares of the company's common stock upon vesting. These RSUs were granted subject to p...

On August 5, 2025, Joseph John Corso, the Chief Financial Officer of NLIGHT, Inc., reported an update on his stock ownership. The filing indicates that Corso acquired 85,000 restricted stock units (RSUs) on August 5, 2025. These RSUs represent the right to receive shares of the company's common stock upon vesting. The ...

Scott H. Keeney, President and CEO of nLIGHT, Inc., reported an update on his stock ownership as of August 5, 2025. Keeney acquired 233,334 restricted stock units (RSUs) on this date, which represent the right to receive shares of the company's common stock upon vesting. These RSUs are subject to performance- and servi...

Tessari Eben, the Chief Operating Officer of Kiniksa Pharmaceuticals International, plc, reported several transactions involving the company's Class A Ordinary Shares. On July 15, 2025, Eben acquired 752 shares at $15.63 per share under the company's 2018 Employee Share Purchase Plan. On August 5, 2025, Eben exercised ...

On August 5, 2025, Richard P. Wallace, the President and CEO of KLA Corp, reported two transactions involving the company's common stock. The first transaction involved the vesting of 9,648.021 shares, which were automatically withheld to cover required tax withholding. The fair market value of the shares was $915.62 p...

On August 5, 2025, Brian Lorig, EVP of KLA Global Services, reported two transactions involving KLA Corp common stock. In the first transaction, 952.68 shares were disposed of at a price of $915.62 per share, leaving him with 11,700.045 shares. This transaction was related to the vesting of performance-based restricted...

On August 5, 2025, Bren D. Higgins, EVP & Chief Financial Officer of KLA Corp, reported two transactions involving KLA common stock. The first transaction involved the vesting of 2,263.08 shares, with shares automatically withheld to cover tax obligations. The second transaction involved the vesting of 754.112 shares, ...

On August 5, 2025, Ahmad A. Khan, President of Semiconductor Products & Customers at KLA CORP, reported two transactions involving KLA common stock. The first transaction involved the vesting of 2,501.064 shares, with shares automatically withheld to cover tax obligations. The second transaction involved the vesting of...

On August 5, 2025, Mary Beth Wilkinson, EVP, CLO, and Secretary of KLA Corp, engaged in several transactions involving the company's common stock. These transactions included the vesting of performance-based restricted stock units (RSUs) and the sale of shares. Specifically, 823.363 shares were disposed of at $915.62 p...

The filing details transactions involving KLA CORP's common stock by Virendra A. Kirloskar, Senior Vice President and Chief Accounting Officer. On August 5, 2025, Kirloskar disposed of shares through three transactions. The first transaction involved the vesting of performance-based restricted stock units, resulting in...

On August 6, 2025, Todd R. Sutherland, President of the E&S Lines Segment at James River Group Holdings, Ltd., was granted 42,955 restricted share units (RSUs) under the company's equity compensation plan. These RSUs are payable solely in common shares of the issuer and will vest in three equal annual installments on A...

Samantha Pearce, EVP and Chief Commercial Officer of Jazz Pharmaceuticals plc, reported a transaction involving the disposal of 577 ordinary shares on August 5, 2025. The shares were sold at a price of $116.10 per share, resulting in a total transaction value of approximately $66,989.70. Following this transaction, Pea...

Chad Patterson, the Chief Commercial Officer of iRhythm Technologies, Inc., sold 2,555 shares of the company's common stock on August 6, 2025, at a price of $158.97 per share. This transaction was executed under a Rule 10b5-1 trading plan established on November 25, 2024. Following the sale, Patterson owns 43,667 share...

On August 5, 2025, Kevin Bitterman, a director of Disc Medicine, Inc., sold 395 shares of common stock at a price of $60.95 per share, pursuant to a Rule 10b5-1 trading plan dated January 31, 2025. Following this transaction, Bitterman owns 625,082 shares directly and indirectly through various entities. The shares are...

Lu Yufang, Chief Medical Officer of ImageneBio, Inc., filed a Form 4 on August 7, 2025, reporting transactions on July 25, 2025. The filing details the acquisition of employee stock options following the merger of Inmagene Biopharmaceuticals with ImageneBio. The options include the right to buy shares of common stock a...

Gregory S. Daily, Chief Executive Officer and Director of i3 Verticals, Inc., reported changes in his ownership of the company's securities. On August 6, 2025, Daily transferred 335,511 Common Units to the CFD 2025 Exempt Irrevocable Trust for no consideration. These Common Units can be redeemed for an equal number of ...

Steven M. Quirk, the Chief Brokerage Officer of Robinhood Markets, Inc., sold 40,131 shares of Class A Common Stock on August 5, 2025. The transaction was executed at a weighted-average price of $104.7081 per share, with prices ranging from $103.29 to $107.15. This sale was conducted pursuant to a Rule 10b5-1 trading p...

On August 5, 2025, Ping Zhang, a director of Gyre Therapeutics, Inc., was granted a stock option to purchase 250,000 shares of the company's common stock at an exercise price of $6.92 per share. The option vests over four years, with 25% vesting on August 5, 2026, and the remaining 75% vesting in equal monthly installm...